JP2002515046A - 骨粗鬆症を含む閉経後疾患を治療する方法 - Google Patents

骨粗鬆症を含む閉経後疾患を治療する方法

Info

Publication number
JP2002515046A
JP2002515046A JP51283798A JP51283798A JP2002515046A JP 2002515046 A JP2002515046 A JP 2002515046A JP 51283798 A JP51283798 A JP 51283798A JP 51283798 A JP51283798 A JP 51283798A JP 2002515046 A JP2002515046 A JP 2002515046A
Authority
JP
Japan
Prior art keywords
idoxifen
estrogen
bone
osteoporosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP51283798A
Other languages
English (en)
Japanese (ja)
Inventor
ブラッドビアー，ジェレミー・エヌ
ゴーウェン，マキシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2002515046A publication Critical patent/JP2002515046A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP51283798A 1996-09-06 1997-09-03 骨粗鬆症を含む閉経後疾患を治療する方法 Pending JP2002515046A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US60/025,439 1996-09-06
US5066697P 1997-06-24 1997-06-24
US60/050,666 1997-06-24
PCT/US1997/015474 WO1998009519A1 (en) 1996-09-06 1997-09-03 Method of treating post menopausal diseases, including osteoporosis

Publications (1)

Publication Number Publication Date
JP2002515046A true JP2002515046A (ja) 2002-05-21

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
JP51283798A Pending JP2002515046A (ja) 1996-09-06 1997-09-03 骨粗鬆症を含む閉経後疾患を治療する方法
JP51283898A Pending JP2002515047A (ja) 1996-09-06 1997-09-03 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP51283898A Pending JP2002515047A (ja) 1996-09-06 1997-09-03 新規方法

Country Status (16)

Country Link
EP (2) EP0929216A4 (xx)
JP (2) JP2002515046A (xx)
KR (2) KR20000068473A (xx)
CN (2) CN1236313A (xx)
AR (1) AR008155A1 (xx)
AU (2) AU4409797A (xx)
BR (2) BR9711681A (xx)
CA (2) CA2264943A1 (xx)
CO (2) CO5070658A1 (xx)
CZ (1) CZ76699A3 (xx)
IL (1) IL128645A0 (xx)
NO (2) NO991097D0 (xx)
PL (2) PL332278A1 (xx)
TR (2) TR199900504T2 (xx)
TW (1) TW411273B (xx)
WO (2) WO1998009619A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5749998A (en) * 1997-02-11 1998-08-26 Novo Nordisk A/S Methods for treatment or prophylaxis of menopausal symptoms
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260066B1 (en) * 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
WO1994006762A1 (en) * 1992-09-15 1994-03-31 Merrell Dow Pharmaceuticals Inc. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
AU4247397A (en) 1998-03-26
JP2002515047A (ja) 2002-05-21
CO4920218A1 (es) 2000-05-29
WO1998009619A1 (en) 1998-03-12
NO991096L (no) 1999-03-05
NO991097L (no) 1999-03-05
CN1236299A (zh) 1999-11-24
TW411273B (en) 2000-11-11
WO1998009519A1 (en) 1998-03-12
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
BR9711676A (pt) 1999-08-24
EP0929216A1 (en) 1999-07-21
CZ76699A3 (cs) 1999-08-11
PL332278A1 (en) 1999-08-30
TR199900506T2 (xx) 1999-07-21
AR008155A1 (es) 1999-12-09
EP0927029A1 (en) 1999-07-07
TR199900504T2 (xx) 1999-06-21
EP0927029A4 (en) 2001-06-13
NO991097D0 (no) 1999-03-05
IL128645A0 (en) 2000-01-31
NO991096D0 (no) 1999-03-05
PL332038A1 (en) 1999-08-16
CA2264775A1 (en) 1998-03-12
CN1236313A (zh) 1999-11-24
KR20000068473A (ko) 2000-11-25
EP0929216A4 (en) 2001-04-04
CO5070658A1 (es) 2001-08-28
KR20000068472A (ko) 2000-11-25
CA2264943A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
KR101141763B1 (ko) 체중 증가의 치료 및/또는 억제에 사용하는 약학 조성물
Evans et al. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia
RU2132682C1 (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови и фармацевтический препарат
JPH06234632A (ja) ベンゾチオフェン類を含有する医薬組成物
KR20000023633A (ko) 배합된 약제학적 에스트로겐-안드로겐-프로제스틴 경구 피임약
JPH06199665A (ja) ベンゾチオフェン類を含有する医薬製剤
HOL et al. Selective estrogen receptor modulators and postmenopausal women's health
HUT72638A (en) Pharmaceutical compositions containing benzotiophene derivative for inhibiting bone loss and for lowering serum cholesterol and process for its preparation
JPH10513152A (ja) 抗黄体ホルモンおよびプロゲスチンを含有する周期相ホルモン養生法
JP2001515038A (ja) エストロゲン依存性疾患および障害の予防または治療方法
AU2003210757B2 (en) Method of hormonal therapy
Legha et al. Nafoxidine–‐an antiestrogen for the treatment of breast cancer
JP2002515484A (ja) ２−フェニルインドール化合物およびエストロゲン製剤からなる組成物
JPH11507051A (ja) 骨損失を最少にする方法
Palacios The future of the new selective estrogen receptor modulators
RU2320339C2 (ru) Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы
JP2002515046A (ja) 骨粗鬆症を含む閉経後疾患を治療する方法
US4820736A (en) Use of clomiphene to predict fertility in a human female
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
Stovall et al. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms
Fitzpatrick et al. Gender-related differences in vascular smooth muscle cell proliferation: Implications for prevention of arteriosclerosis
MXPA99002213A (en) Method of treating post menopausal diseases, including osteoporosis
Marín et al. Clinical pharmacology of selective estrogen receptor modulators (SERMs)
CA2223174A1 (en) Methods for minimizing bone loss
WO1999000019A1 (en) Methods of treating the symptoms of atrophic vaginitis and altered sexual behavior in postmenopausal women